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A B S T R A C T
Background: Numerous paediatric febrile neutropenia (FN) clinical decision rules (CDRs) have been derived.
Validation studies show reduced performance in external settings. We evaluated the association between
variables common across published FN CDRs and bacterial infection and recalibrated existing CDRs using
these data.
Methods: Prospective data from the Australian-PICNICC study which enrolled 858 FN episodes in children
with cancer were used. Variables shown to be significant predictors of infection or adverse outcome in >1
CDR were analysed using multivariable logistic regression. Recalibration included re-evaluation of beta-coef-
ficients (logistic model) or recursive-partition analysis (tree-based models).
Findings: Twenty-five unique variables were identified across 17 FN CDRs. Fourteen were included in >1 CDR
and 10 were analysed in our dataset. On univariate analysis, location, temperature, hypotension, rigors,
severely unwell and decreasing platelets, white cell count, neutrophil count and monocyte count were signif-
icantly associated with bacterial infection. On multivariable analysis, decreasing platelets, increasing temper-
ature and the appearance of being clinically unwell remained significantly associated. Five rules were
recalibrated. Across all rules, recalibration increased the AUC-ROC and low-risk yield as compared to non-
recalibrated data. For the SPOG-adverse event CDR, recalibration also increased sensitivity and specificity
and external validation showed reproducibility.
Interpretation: Degree of marrow suppression (low platelets), features of inflammation (temperature) and
clinical judgement (severely unwell) have been consistently shown to predict infection in children with FN.
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1. Introduction
Advancements in the management of paediatric cancer, driven
largely by risk stratification, have resulted in significant improve-
ments in overall survival [1]. While cancer treatment becomes
increasingly personalised, similar evolutions in the management of
the complications of care are lacking. Regarding infectious complica-
tions, there are increasing global efforts to adopt similar risk-adapted
approaches to prediction, prevention and treatment [2]. Specifically,
risk stratification in fever and neutropenia (FN), one of the most
common complications of care, is recommended although wide-
spread uptake has not been realised [3-6].
To date, there is no international consensus as to the most impor-
tant outcome that should be predicted in children with FN [3]. Clini-
cal decision rules (CDRs) have been designed to predict a spectrum of
outcomes ranging from bacteraemia alone through to combinations
of any bacterial, viral or fungal microbiologically defined infection
and other clinical adverse outcomes such as sepsis and intensive care
(ICU) admission [7]. More recently, the outcome of likely bacterial
infection has been proposed, based on the understanding that this
underscores the rationale for the early introduction of broad-spec-
trum antibiotics [8,9]. Prompt exclusion of bacterial infection has the
potential to reduce unnecessary antibiotic exposure, thereby decreas-
ing hospital length of stay and improving resource allocation.
The variation in the outcomes predicted in paediatric FN CDRs
may, in part, explain the differences observed in the performance of
these rules [7]. Many of these CDRs were also derived over two deca-
des ago and therefore do not account for recent advancements in the
treatment of childhood cancer. Rather than continually deriving new
risk prediction rules, recalibration of existing rules is advised but
rarely performed [10]. Such a strategy would enable clinical variables,
consistently shown to predict infection, to be re-examined in con-
temporary datasets and the weight assigned to these variables read-
justed as required. This approach avoids the loss of valuable scientific
data by combing prior information captured in derivations studies,
with contemporary information about a new, albeit similar, popula-
tion at risk [11].
The objectives of this study are to (i) evaluate the strength of asso-
ciation between individual clinical variables common across pub-
lished paediatric FN clinical decision rules and bacterial infection and
(ii) recalibrate existing CDRs using these data. We hypothesise that
we will identify clinical variables that are shown to be consistently
predictive of infection across multiple different studies.
2. Methods
Prospectively collected data from the Australian Predicting Infec-
tious ComplicatioNs in Children with Cancer (PICNICC) study was
used for this analysis (Australian New Zealand Clinical Trials Registry
12616001440415) [9]. Eight tertiary paediatric cancer centres in Aus-
tralia contributed data to this study which was open to recruitment
from November 2016 to January 2018. A total of 858 FN episodes in
462 children with cancer were enrolled and available for analysis.
Methodology and reporting of results followed the Transparent
Reporting of a multivariable prediction model for Individual Progno-
sis Or Diagnosis statement (TRIPOD) [12].
Detailed methodology is described elsewhere [9]. Data on conse-
cutive episodes of FN in children (age <18yrs) with cancer or haema-
tological malignancy were prospectively collected. Episodes were
included if they had a documented fever and neutropenia. Episodes
were excluded if FN treatment commenced at a non-participating
site, the patient had undergone a hematopoietic stem cell transplant
within the preceding three months or the episode occurred while
they were receiving concurrent intravenous or oral antibiotics
(excluding prophylaxis). The research assistant collecting the data
was blinded to the CDR variables and outcome definitions and data
accuracy was verified by the project manager and site investigators
(oncology or infectious diseases physician).
Research in context
Evidence before this study
Risk stratification in fever and neutropenia (FN), one of the
most common complications of childhood cancer care, is rec-
ommended in international paediatric FN guidelines. Recalibra-
tion of existing risk prediction rules is advised as it avoids the
loss of valuable scientific data by combing prior information
captured in derivations studies, with contemporary informa-
tion about a new, albeit similar, population at risk. We searched
PubMed, with no restrictions on language or publication date,
using the search terms: (febrile OR fever) AND (neutropenia OR
neutropenic) AND (clinical decision rule OR risk prediction)
AND (recalibration). Only one paediatric FN clinical decision
rule (CDR) has undergone recalibration however, to date, it has
not been implemented into practice.
Added value of this study
Using a large, prospectively collected database, designed to val-
idate paediatric FN CDRs, we have evaluated the strength of
association between individual clinical variables common
across published paediatric FN rules and bacterial infection.
Using these data we have recalibrated an additional five CDRs,
reducing research waste and applying the findings to a contem-
porary population. We confirm a number of important and
accessible variables remain consistently predictive of infection,
in particular degree of marrow suppression (low platelets), fea-
tures of inflammation (height of temperature) and clinical
judgement (patient assessed as “severely unwell”). By applying
previously published low-risk FN program eligibility criteria,
we also highlight the importance of additional safe guards and
a structured approach to implementing these pathways.
Implications of all the available evidence
In the context of a global pandemic, managing children with
cancer and FN in 2020 using a standard inpatient approach may
not be feasible for many centres. Safe and reliable pathways for
identifying children at low risk of infection who can be treated
at home with short-course oral or intravenous antibiotics are
urgently required. Centres considering implementing any of
the recalibrated rules should do so as part of a structured low-
risk FN program and ensure appropriate measures are in place
to monitor the clinical and, where possible, the economic and
quality of life impact of this model of care.
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The primary outcome for this study was ‘likely bacterial infection'
(as defined below). Secondary outcomes included bacteraemia, inten-
sive care unit (ICU) admission, 30-day mortality and eligibility for
home based care. In the original dataset, clinical variables were col-
lected at FN presentation and outcomes were collected at the end of
FN episode and day 30. The date and time that an infection was first
identified was also available in the dataset.
A formal low-risk FN program was not in use during the study
period and FN episodes were managed according to state-based hos-
pital FN guidelines that were in keeping with international recom-
mendations [3]. Cessation of antibiotics and hospital discharge was
typically considered in patients with marrow recovery, negative cul-
tures and at least a 24h period of clinical stability and absence of
fever. Antibacterial prophylaxis (excluding for Pneumocystis jirovecii
pneumonia) was not routinely used.
2.1. Identification of clinical variables
Seventeen published paediatric FN CDRs were identified on sys-
tematic review of the literature [13-29]. Previously published sys-
tematic reviews were also assessed to ensure all relevant studies
were captured [7,30]. Studies that only reported individual variables
for infection, rather than derived a CDR, were not considered.
Variables selected for analysis in the Australian-PICNICC study
dataset were those that were included in more than one CDR. Dis-
ease-related factors including cancer diagnosis, relapse status, bone-
marrow involvement were not considered, a priori, due to heteroge-
neity between studies in grouping of these diagnoses as well as the
changes to definitions of relapse status over time with availability of
molecular detection of minimal residual disease. Similarly, presence
of a central venous catheter was not included as this present in 98%
patients in this dataset, and was deemed a priori as non-discrimina-
tory [9]. Finally, a documented focus of infection was excluded
because if clinically apparent at presentation it does not need to be
‘predicted’ and, alternatively, if not apparent then this was included
in the outcome rather than predictor.
Rules selected for recalibration were those where all variables
were available in the existing dataset and did not include disease-
related factors, presence of central venous catheter or focus of infec-
tion.
2.2. Definitions
Fever was defined as a single temperature 38°C and neutropenia
as an absolute neutrophil count (ANC) <1000/mm3. ‘Severely unwell’
was defined as severe sepsis or septic shock (as per Goldstein et al)
[31], altered conscious state (Glasgow Coma Score <15 or only
responsive to voice or pain), documented as ‘severely unwell’ or
equivalent in the patient record or either the blood pressure or respi-
ratory rate in the mandatory emergency call range [32].
A likely bacterial infection was defined as any infection with a
microbiologically documented bacterial cause or that was clinically
documented in categories typically attributed to bacterial infection,
including pneumonia, skin and soft-tissue infection, osteomyelitis or
myositis, enterocolitis, otitis media or externa, sinusitis, epididy-
moorchitis, central venous catheter pocket or tunnel infection, phar-
yngitis, perianal abscess or cellulitis, peritonitis or lymphadenitis
[8,9].
A microbiologically documented infection was defined as an
infection that was clinically detectable and microbiologically proven.
Bacteraemia was defined as a recognised pathogen (including organ-
isms associated with mucosal barrier injury in the setting of mucosi-
tis or neutropenia) from 1 blood culture set or common
commensals from 2 blood culture sets drawn on separate occasions
[33]. Eligibility for home based care was defined as no severe sepsis
at presentation, no relapsed/refractory disease, not in induction
chemotherapy, no acute myeloid leukaemia or infant leukaemia, no
hematopoietic stem cell transplant and no-other complication
requiring inpatient care [34,35].
2.3. Statistical analysis
Clinical variables significantly associated with likely bacterial
infection on univariate analysis were entered into a multivariable
model. Logistic regression, with standard errors, was used to identify
variables that remained significant. A p value <0.05 was consider sig-
nificant for all analyses.
Models were updated by a process of recalibration using the out-
come of likely bacterial infection. Recalibration included re-evalua-
tion of beta-coefficients from those rules derived using logistic
regression models, or recursive-partition analysis with selection of
the most parsimonious split for tree-based models [11]. Analyses
were performed using ‘R’ (version 3.6.0) packages ‘glm’ and ‘rpart.’
The 95% confidence intervals were calculated using an assumption of
Normality using the package ‘confint’.
Sensitivity, specificity, positive predictive value and negative pre-
dictive value for each recalibrated CDR for the prediction of likely
bacterial infection were calculated. To determine the overall discrimi-
natory ability, the area under the receiver operating characteristic
curve (AUC-ROC) were also calculated, with 95% confidence interval
derived by 2000-iteration bootstrapping with replacement. To assess
clinical utility, the following missed outcomes were reported where
relevant: bacteraemia, ICU admission, and death.
The sensitivity and specificity of the Swiss Paediatric Oncology
Group (SPOG) CDRs at day 2 was assessed using methodology
described by this group [28]. Using variables collected at presenta-
tion, the sensitivity of the rule at day 2 (between 0900am and
1100am) was determined by combining the information on episodes
with the outcome known at that time with the results of prediction
on the remaining episodes.
Validation of the best performing recalibrated CDR was done in a
separate dataset of 650 consecutive episodes of FN [36]. These data
were collected retrospectively for the purpose of validating paediatric
FN CDRs and included episode occurring between November 2011
and June 2015 at a single site [36,37]. The sensitivity, specificity, posi-
tive predictive value and negative predicative value of the recali-
brated CDR for the prediction of likely bacterial infection was
calculated in this separate dataset. The recalibrated rule was consid-
ered reproducible if there was overlapping sensitivity or specificity in
the prospective recalibration (n=858) and retrospective validation
(n=650) cohorts [36].
2.4. Ethics
The study had national and site specific Human Research Ethics
Committee approval and informed patient consent was obtained.
2.5. Role of funding source
The funding source had no involvement in study design, data col-
lection, analysis or manuscript preparation or approval.
3. Results
Outcomes predicted across the 17 FN CDRs included in the analy-
sis were bacteraemia in seven [13-19], microbiologically defined
infection in one [20] and the composite outcome of ‘adverse event’ in
nine which included various combinations of infection and medical
complications such as admission to the ICU [21-29]. Twenty five
unique variables were identified which were grouped into factors
relating to; underlying disease, chemotherapy, location before FN
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onset, patient factors, clinical presentation, marrow suppression, bio-
markers and focus for infection (Table 1).
Fourteen unique variables were included in more than one pub-
lished CDR of which 10 were analysed in our dataset (Table 1). Three
were not assessed as they were excluded a priori (disease/chemo-
therapy-related factors, presence of central venous catheter and focus
of infection). C-reactive protein was also excluded as this was not
available in the primary dataset. The 10 variables included in the
analysis were location (inpatient versus outpatient), presenting
symptoms (clinically unwell, maximum temperature, rigors, hypo-
tension), degree of marrow suppression (haemoglobin, platelets,
white cell count (WCC), absolute neutrophil count (ANC), absolute
monocyte count (AMC)).
In 198 (23%) FN episodes a likely bacterial infection was docu-
mented including 108 (13%) with a bacteraemia. Detailed demo-
graphic has been reported previously [9]. The median age of
participants was 5.8 years (interquartile range, 3.5-10.7 years) and
449 (52%) had acute leukaemia, 66 (8%) had lymphoma and 343
(40%) had a solid tumour.
On univariate analysis, location, temperature, hypotension, rigors,
severely unwell and decreasing platelets, WCC, ANC and AMC were
significantly associated with likely bacterial infection (Table 2). On
multivariable analysis, decreasing platelets, increasing temperature
and the appearance of being clinically unwell remained significantly
associated (Table 2). The model had an AUC-ROC of 067 (95% CI
063-071) for the prediction of bacterial infection and, at a thresh-
old of 15%% the sensitivity was 93% and specificity was 23% (Table 3).
The beta coefficients for the model are available in Table 1 of the
online supplement.
3.1. Rule recalibration
Of the seventeen CDRs identified, five were recalibrated. Five
CDRs were not recalibrated as they included variables unavailable in
the dataset [14,18,22,25,27]. A further six included disease-related
variables [13,16,20,21,23,29] and one included presence of central
venous catheter (Rondinelli) [26].
Of the five rules recalibrated, three used AMC and temperature
(Klaassen, Baorto, Rackoff), one used haemoglobin, platelets, rigors
and requirement for in-patient care (SPOG-bacteraemia) and one
used chemotherapy intensity, haemoglobin, platelets and WCC
(SPOG-adverse event) (Table 4). The optimal AMC cut-off was 0015
cells/mm3 and temperature was 395°C, compared with their original
values of 01 to 0155 cells/mm3 and 39°C. Both the SPOG-bacterae-
mia and SPOG-adverse event rule recalibrations set each of the three
factors at the same weighting (1), and haemoglobin was removed as
uninformative.
The sensitivity and specificity of the recalibrated CDRs is available
in Table 5. Across all rules, recalibration increased the AUC-ROC and
low-risk yield as compared to non-recalibrated data (Table 2, online
supplement) [9]. In the SPOG-adverse event rule, recalibration also
increased sensitivity and specificity, while for the remaining CDRs
sensitivity reduced.
At a threshold of zero, the recalibrated SPOG-adverse event CDR
had the highest sensitivity for prediction of bacterial infection and
the performance of this rule was further explored (Table 6). Valida-
tion of this recalibrated rule indicates reproducibility with overlap-
ping sensitivity across all thresholds and both sensitivity and
specificity at threshold of 2 (Table 3, online supplement). Details of
clinically significant infections and adverse outcomes, stratified by
the recalibrated SPOG-adverse event score is provided in Table 7. The
proportion of episodes with a likely bacterial infection (including
bacteraemia) was 107%, 164%, 232% and 381%, for risk-scores 0,
1, 2 and 3, respectively. Applying previously published eligibility cri-
teria for home-based management of FN in children, the overall num-
ber of patients eligible for early transfer home would be 488 [34].
Notably, only one of 24 ICU admissions would have been missed in a
patient that scored the maximum of three.
4. Discussion
Using a large, multisite, prospectively collected dataset we identi-
fied nine clinical variables, routinely available in the initial assess-
ment of children with cancer and FN, that are associated with likely
bacterial infection. These variables, either alone or in various combi-
nations, have similarly been shown to be associated with infection in
this population. A new model, incorporating markers of marrow sup-
pression (decreasing platelets), degree of acute inflammation (tem-
perature) and clinical presentation (well or unwell) was derived and,
while very sensitive, the overall discriminatory ability was poor. Five
existing FN CDRs were also recalibrated using the outcome of likely
bacterial infection. Across all rules, recalibration improved the CDRs
ability to predict bacterial infection, most notably for the SPOG-
adverse event rule [28].
The recalibrated SPOG-adverse event rule had the best overall
performance in our dataset [28]. Similar to previous derivation and
validation studies, the sensitivity and negative predictive value of
this recalibrated rule for prediction of likely bacterial infection
improved after a period of in-hospital observation [28,36]. When
applying additional safety-net criteria, as described in adult and pae-
diatric low-risk FN programs, 57% of FN episodes would have been
eligible for home-based care with very few missed infections and
only one severe adverse outcome [34,35]. A suggested approach to
implementation of this rule is available, and includes a minimum in-
hospital observation period depending on the score [38]. To recali-
brate the Swiss-derived SPOG-adverse event rule, prospective data
from this Australian study was used in collaboration with the United
Kingdom (UK) PICNICC research group [39]. We propose this recali-
brated rule, developed from data collected in Australia, UK and Swit-
zerland is called the AUS-rule to differentiate it for future use.
Our study did not show an association between haemoglobin and
infection. Haemoglobin has previously been identified as a predictor
of infection in at least six FN CDR derivation studies
[14,19,20,25,26,28]. Curiously, an elevated haemoglobin was predic-
tive of bacteraemia or adverse outcome in four studies, of which
three were from the SPOG research network [14,19,28]. This associa-
tion was further explored and the authors concluded that dehydra-
tion, rather than recent red blood cell transfusion, may in part
explain the counterintuitive findings [40]. They also showed that
haemoglobin was bimodally distributed, with severe anaemia also
being associated with severe infection.
When selecting a paediatric FN CDR for implementation consider-
ation must be given to timely access to the relevant clinical variables.
Three of the recalibrated CDRs included monocyte count that
requires manual assessment of the blood film and therefore may not
be readily available outside standard ‘business hours.’[15,17,24] Reli-
ability is also an important factor and may, in part, explain why many
FN CDR developers have explored objective markers such as full
blood examination parameters and temperature over more subjec-
tive measures such as severely unwell. However the latter has been
shown to be consistently predictive of infection or adverse outcome
on multivariate analyses suggesting, not surprisingly, that is an
important component of the risk stratification process [20,39].
Although we were unable to re-evaluate all published FN CDRs,
our study focused on rules that included variables shown to be pre-
dictive across multiple settings. Furthermore, while post hoc, this
analysis was done using a large, prospectively collected database
designed to capture variables and outcomes specific to paediatric FN
risk prediction tools. This is also the first paediatric FN study to recali-
brate the five FN CDRs, thereby preserving valuable discoveries made
around the world and enhancing generalizability in a contemporary
Australian dataset. It is important to acknowledge that the CDRs
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Table 1
Comparison of individual variables common across paediatric febrile neutropenia clinical decision rules
Dis Chemo Loc Patient factors Clinical presentation Marrow status Biomarker Focus Total
Intensity IP Age CVC Nut. CU Temp Rig. Alt. MS Cap. Fluid BP Other* Hb Plat WCC ANC AMC IL-8 CRP
Bacteraemia
Ammann-2004[13]     4
Ammann 2003[14] #      7
Baorto [15]  1
Lucas [16]     4
Rackoff [17]   2
Santolaya [18] ^    5
SPOG-bact [19]     4
Microbiologically documented infection
PICNICC [20]       6
Adverse outcome
Alexander [21] **      10
Das [22]      5
Hakim [23]     4
Klaassen [24]  1
Miedma [25]    3
Paganini [29]   2
Rondinelli [26]      5
SPOG-AE [28]     4
West [27]   2
Dis is disease; chemo, chemotherapy; loc, location of FN onset; IP, inpatient; CVC, central venous catheter; nut, nutrition; CU, clinically unwell; temp, temperature; cap is capillary refill; BP, blood pressure; Hb, haemoglobin; Plat,
platelet; WCC, white cell count; ANC, absolute neutrophil count; AMC, absolute monocyte count; IL-8, interleukin 8; CRP, C-reactive protein; focus, focus of infection; SPOG, Swiss Paediatric Oncology Group; bact, bacteraemia; AE,
adverse event. *includes other vital signs, CXR changes, Mucositis, GI symptoms; #includes malignancy type and bone marrow involvement; ^includes malignancy type and time from chemotherapy; ** included type of cancer and
relapse status
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included in this analysis were derived in the era of traditional cyto-
toxic immunosuppressive cancer treatment and may not reflect novel
approaches such as chimeric antigen receptor T-cell therapy and
checkpoint inhibition. While recalibration may, in part, account for
this, further research is required to understand risk factors and pre-
dictors of severe infection in these patients, many of whom may not
present with the traditional FN syndrome.
Our study has re-evaluated and refined predictors of bacterial
infection in children with cancer. Somewhat reassuringly, there are
key components of risk prediction that remain consistent over time
and location, namely the more unwell looking and the more marrow
suppressed patients are, the more likely they are to have a bacterial
infection. By exploring these variables consistently shown to be pre-
dictive, as well as recalibrating existing CDRs, we have avoided the
Table 2
Univariate and multivariable association with likely bacterial infection
Univariate Multivariable
OR Lower CI Upper CI p-value OR Lower CI Upper CI p-value
Requirement inpatient care 1¢90 1¢35 2¢66 <0¢001 0¢39 0¢09 1¢59 0¢189
Temperature* 1¢46 1¢12 1¢91 0¢005 1¢67 1¢15 2¢42 0¢009
Hypotension** 2¢03 1¢11 3¢71 0¢022 0¢29 0¢08 1¢13 0¢076
Rigors 1¢88 1¢14 3¢10 0¢013 0¢91 0¢43 1¢92 0¢818
Severely unwell*** 2¢36 1¢42 3¢92 0¢001 9¢3 1¢76 49¢21 0¢009
Haemoglobin 0¢97 0¢89 1¢05 0¢449 0¢96 0¢92 1 -
Platelets^ 0¢93 0¢91 0¢99 <0¢001 0¢95 0¢55 1¢65 0¢024
White cell count# 0¢48 0¢35 0¢66 <0¢001 0¢84 0¢58 1¢22 0¢850
Absolute neutrophil count# 0¢64 0¢49 0¢84 0¢001 0¢83 0¢55 1¢25 0¢371
Absolute monocyte count# 0¢59 0¢44 0¢80 0¢001 0¢39 0¢09 1¢59 0¢380
OR, odds ratio; CI, confidence interval; SE, standard error;
*Per degree above 37°C; **defined as systolic blood pressure below the mandatory emergency call threshold for age;
***defined as as severe sepsis or septic shock, altered conscious state, documented as ‘severely unwell’ or equivalent in the
patient record or either the blood pressure or respiratory rate in the mandatory emergency call range; ^Per 10-platelet” incre-
ment (i.e. 30 £ 10^9/L to 40 £ 10^9/L); #natural log
Table 3
Sensitivity and specificity of “new rule” at different thresholds
Low risk threshold Low risk, n (%) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
10% 92 (10¢7) 96¢5 (92¢9-98¢3) 13¢0 (10¢7-15¢8) 25¢1 (22¢1-28¢3) 92¢4 (85¢1-96¢3)
15% 164 (19¢1) 92¢9 (88¢4-95¢7) 23¢0 (19¢9-26¢4) 26¢7 (23¢5-30¢1) 91¢5 (86¢2-94¢9)
20% 281 (32¢8) 82¢7 (76¢9-87¢4) 37¢8 (34¢2-41¢6) 28¢7 (25¢1-32¢5) 87¢9 (83¢6-91¢2)
PPV, is positive predicitive value; NPV, negative predicitive value; CI, confidence interval
Table 4
Comparison of derivation and recalibrated (to predict bacterial infection) variables denoting ‘high risk’
Derivation variables Recalibrated variables
Baorto [15] AMC < 155 cells/mm3 AMC<15 cells/mm3
Rackoff [17] High risk = AMC < 100 cells/m3 and temperature 39°C;
Low risk = AMC  100 cells/mm3; intermediate risk = AMC
<100 cells/mm3 and temperature <39°C
High risk = AMC < 15 cells/m3 and temperature 39¢5°C;
Low risk = AMC  15 cells/mm3; intermediate risk = AMC
<15 cells/mm3 and temperature <39¢5°C
SPOG-bacteraemia [19] Applied after 24 hours.
Score for shaking or chills = 5; Hb 90g/L = 3; platelet <50
g/L = 3; Other need for inpatient care = 3
Score for shaking or chills = 1; platelet<50 g/L = 1; Other need
for inpatient care = 1
Klaassen [24] AMC < 100 cells/mm3 AMC<15 cells/mm3
SPOG-AE [28] Applied after 24 hours.
Total score  9 = high risk
Score for preceding chemotherapy more intensive than ALL
maintenance =4; Hb  90 g/L =5; WCC < 300 cells/mm3 = 3;
platelet <50 g/L =3
Score for preceding chemotherapy more intensive than ALL
maintenance =1; WCC < 300 cells/mm3 = 1; platelet <50 g/
L =1
AMC is absolute monocyte count; Hb, haemoglobin
Table 5
Sensitivity and specificity of recalibrated (RC) paediatric febrile neutropenia clinical decision rules for prediction of likely bacterial infection.
Low risk, n (%) AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
RC-Baorto [15] 327 (38¢1) 0¢58 (0¢54-0¢63) 70¢7 (64¢0-76¢6) 49¢6 (45¢7-53¢6) 29¢6 (25¢7-33¢9) 84¢9 (81¢0-88¢2)
RC-Rackoff [17]* 385 (44.9) 0¢60 (0¢55-0¢64) 70¢7 (64¢0-76¢6) 49¢6 (45¢7-53¢4) 29¢6 (25¢7033¢9) 84¢9 (81¢0-88¢2)
RC-SPOG bact [19] (LR0) (n=825) 312 (37¢8) 0¢64 (0¢59- 0¢67) 77¢0 (70¢5-82¢4) 42¢3 (38¢5-46¢2) 28¢7 (24¢9-32¢7) 86¢0 (81¢6-89¢3)
RC-Klaassen [24] 327 (38¢1) 0¢58 (0¢54-0¢63) 70¢7 (64¢0-76¢6) 49¢6 (45¢7-53¢6) 29¢6 (25¢7-33¢9) 84¢9 (81¢0-88¢2)
RC-SPOG AE [28] (LR0) 84 (9¢8) 0¢64 (0¢60-0¢68) 93¢5 (91¢6-97¢6) 11¢4 (9¢1-14¢0) 24¢4 (21¢5-27¢6) 89¢3 (80¢9-94¢3)
AUC-ROC is area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predicitive value; NPV, negative predicitive value; LR, low
risk; RC, recalibrated
*intermediate and high-risk combined into a single high-risk group
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loss of valuable scientific data captured in derivation studies around
the world. The recalibrated SPOG-adverse event rule, or AUS-rule,
showed the best performance in our dataset. The additional safety-
net criteria further enhanced the potential safety of this rule empha-
sising that, while an important component of the risk stratification
process, CDRs should not be used in isolation. Centres considering
using this recalibrated rule should do so as part of a structured low-
risk FN program, and ensure appropriate measures are in place to
monitor the clinical and, where possible, the economic and quality of
life impact of this model of care. A suggested approach to implemen-
tation of such a program is available through the Australian National
Centre for Infections in Cancer and includes relevant organisational-,
clinician- and patient-level resources [38]. Adaptations to this model
should be made in consultation with local stakeholders (such as
oncology, infectious diseases, emergency medicine, nursing and
pharmacy) as well as patient and family representatives to enhance
the uptake, safety and appropriate use of home-based FN care.
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